Delivery Order SPE2DR25D2014-SPE2DR26FZ97V
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,780.92 to AmerisourceBergen Drug Corp for the supply of Losartan-HCL 100-12.5 mg tablets (90-count) on September 9, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $4,560.68 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count units) on October 31, 2025, with an ultimate completion date of November 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,704.97 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on September 10, 2025, with completion scheduled for September 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,358.35 to AmerisourceBergen Drug Corp for the supply of Losartan-HCL 100-25 mg tablets (90-count) under a firm fixed-price contract. The contract was competitively awarded without set-aside designation and is scheduled for completion by December 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this order. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a ceiling value of $1,867.39. This firm fixed-price delivery order has an ultimate completion date of October 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded among...
- The Defense Logistics Agency awarded a delivery order valued at $3,662.10 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) on November 18, 2025, with completion expected by November 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Losartan-HCL 100-12.5 mg tablets (90-count) with a ceiling value of $4,915.61. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The order is scheduled for completion by October 31, 2025, and will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.05 to AmerisourceBergen Drug Corp for the supply of Losartan-HCZ 100-12.5 mg tablets in a 90-day supply. This competitively awarded, firm fixed-price delivery order was issued on November 12, 2025, with an ultimate completion date of November 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,850.96 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on December 1, 2025, with an ultimate completion date of December 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $5,776.24 to AmerisourceBergen Drug Corp for the supply of Losartan-HCT 100-25 mg tablets (90-count) on September 23, 2025, with completion expected by September 24, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ97VDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,260.98 to AmerisourceBergen Drug Corp for the supply of Losartan-HCL 100-12.5 mg tablets in quantities of 90, with an ultimate completion date of December 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen Drug Corp's extensive pharmaceutical supply relationship with the DLA Medical Supply Chain. The award is issued under the company's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This comprehensive prime contract vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support military healthcare systems globally, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities. The company's consistent receipt of competitively awarded delivery orders across various therapeutic domains demonstrates its established capability to meet federal pharmaceutical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 12/14/25 |